Protalix BioTherapeutics Inc PLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.44
- Day Range
- $2.39–2.48
- 52-Week Range
- $1.36–3.19
- Bid/Ask
- $2.40 / $2.50
- Shares Outstanding
- 80.57M
- Market Cap
- $192.57M
- Volume/Avg
- 534,967 / 718,711
Key Statistics
- Price/Earnings (Normalized)
- 12.58
- Price/Sales
- 2.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 226
- Website
- https://www.protalix.com
Valuation
|
Metric
|
PLX
|
|---|---|
Price/Earnings (Normalized) | 12.58 |
Price/Book Value | 2.86 |
Price/Sales | 2.51 |
Price/Cash Flow | 9.21 |
Price/Earnings
PLX
Financial Strength
|
Metric
|
PLX
|
|---|---|
Quick Ratio | 1.97 |
Current Ratio | 3.15 |
Interest Coverage | 12.86 |
Quick Ratio
PLX
Profitability
|
Metric
|
PLX
|
|---|---|
Return on Assets (Normalized) | 20.45% |
Return on Equity (Normalized) | 32.55% |
Return on Invested Capital (Normalized) | 29.38% |
Return on Assets
PLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$nfZ>k | LOCK|<^w? | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Cy<$VH | LOCK|^!qLm | $70B | |||
| argenx SE ADR
ARGX
| LOCK|wq<Z&s | LOCK|Rj | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%Grz#L | LOCK|PFZ! | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>p@jw%h | LOCK|dWZ | $36B | |||
| Moderna Inc
MRNA
| LOCK|cr^%$K | LOCK|<w> | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|V%^kp<p | LOCK|dBrc$ | $25B | |||
| Incyte Corp
INCY
| LOCK|lv&L>lS | LOCK|%^^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|h?<qmP# | LOCK|>R | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|#@!&?#C | LOCK|s> | $16B |
United States